Integra Therapeutics, a prominent player in the field of gene therapy tools aimed at enhancing the precision, efficacy, and safety of advanced treatments, recently closed a pre-Series A investment round totaling €10.7 million. This funding injection includes contributions from new investors such as the EIC Fund, the venture capital arm of the European Innovation Council (EIC) backed by the European Investment Bank (EIB), which allocated €4 million. Additionally, CDTI Innvierte, a venture capital entity under the Spanish Ministry of Science, Innovation, and University, chipped in €2.7 million. Existing investors like AdBio Partners, Columbus Venture Partners, Invivo Partners, and Takeda Ventures also participated in this round, underscoring their continued support for Integra’s mission. The capital raised will be instrumental in integrating new advancements into the FiCAT gene writing platform, validating next-generation CAR-T therapies during preclinical stages, and expanding FiCAT’s cell engineering capabilities to streamline technology transfer within the pharmaceutical sector.
Integra Therapeutics showcased promising preclinical data for the FiCAT platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) earlier this year. Moreover, the company is actively working on its first gene therapy targeting a rare pediatric liver disease, with financial backing from an EIC Accelerator grant. Avencia Sánchez-Mejías, PhD, CEO and Co-Founder of Integra Therapeutics, expressed gratitude for the investors’ support, emphasizing the company’s commitment to driving innovation in cell and gene therapies to revolutionize the treatment landscape for complex conditions like cancer, autoimmune disorders, and rare diseases. Svetoslava Georgieva, Chair of the EIC Fund Board, highlighted the significance of the investment in propelling the development of transformative therapies that have the potential to make a global impact in the gene therapy domain.
Founded in 2020 as a spinoff from Pompeu Fabra University (UPF) by Dr. Marc Güell and Dr. Avencia Sánchez-Mejías, Integra Therapeutics specializes in pioneering gene editing tools designed to elevate the safety and effectiveness of advanced therapies. Through strategic collaborations with industry leaders like CasZyme, Integra is poised to accelerate its research endeavors and broaden its reach. The EIC Fund, a technology-focused investor supported by the European Commission, plays a pivotal role in funding deep tech innovations across various sectors. By bridging crucial financing gaps, the EIC Fund aims to empower companies in advancing disruptive technologies and bringing them to market successfully. On the other hand, INNVIERTE Economía Sostenible SICC S.M.E., S.A., an initiative established by CDTI under the Ministry of Science, Innovation, and Universities, focuses on fostering business innovation by facilitating venture capital investments in technology-driven and innovative enterprises.
- Integra Therapeutics secures €10.7M in funding to advance gene therapy platforms and validate CAR-T therapies
- The investment round includes support from the EIC Fund and CDTI Innvierte, along with existing investors
- The funds will drive enhancements to the FiCAT gene writing platform, validation of next-gen CAR-T therapies, and expansion of cell engineering capabilities
- Integra Therapeutics is dedicated to revolutionizing the landscape of cell and gene therapies to address complex diseases and transform patient outcomes
Tags: gene therapy, cell therapy, biotech
Read more on pharmabiz.com